Lipocine Inc.
LPCNHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeLipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company carries a $18.1M market cap, placing it firmly in the micro-cap category. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Market Cap
$18.1M
Beta
0.44
P/E (TTM)
—
P/E (Fwd)
-1.77
EPS (TTM)
$-1.98
EPS (Fwd)
$-1.24
ROE
-54.4%
ROA
-33.1%
Cash
$24.7M
Total Debt
$0
Free CF
-$6.0M
52W Change
-32.8%
Annual Financials
Cash vs Debt
Where LPCN stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, LPCN finished 55.58% below its 150-day moving average ($5.20) and 50.22% below its 200-day moving average ($4.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LPCN overbought or oversold?
At the July 15, 2026 close, LPCN's RSI(14) was 36.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lipocine Inc. reports $24.7M in cash and $0 in total debt. Free cash flow is running at -$6.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -54.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $500K to $2.0M.
LPCN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lipocine Inc. and its sector.